InfrafrontierGR/Phenotypos is an expansion of InfrafrontierGR, the Greek node of ESFRI Infrafrontier: The European Infrastructure for phenotyping and archiving of model mammalian genomes, to which Greece is a full partner since 2008.
The proposed expansion of the infrastructure will cover: (a) macroscopic and analytical platforms for detailed description of complex disease phenotypes in mouse models that can be exploited for the clinical/biomarker description of human disease; and (b) the animal modeling and phenotyping of additional important disease areas in which Greek research is also highly competitive, including metabolic and neurological diseases. The three partners that currently form InfrafrontierGR (Fleming, BRFAA and FORTH-IMBB) have complementary, state-of-the-art expertise in the technological platforms addressed by the infrastructure. The next "Phenotypos" phase of the RI involves three new partners (UoA-Med, UoA-NBB and DUTH-MBG), who will bring in complementary expertise for extended phenotypic platforms, links to preclinical and translational programs and outreach to regional research communities.
This second phase of development will complement the “mouse clinic” initiative covered by InfrafrontierGR by renewing, upgrading and expanding its current capacities and establishing new facilities that will allow the integrated study of additional biological parameters towards the generation of essentially complete phenotypic profiles. This will be achieved through the incorporation of systematic screens for an organism’s metabolites and the macroscopic behavioral patterns altered during disease development. The expanded facility will offer comprehensive and standardized services for biomedical discovery to national and European stakeholders both from academia and industry, through the phenotypic analysis of mouse models of chronic degenerative diseases, such as type2 diabetes, atherosclerosis, dementias and cancer, which are now recognized as worldwide epidemics. InfrafrontierGR/Phenotypos aims to enhance research excellence by networking expertise and technological platforms currently located in different research centers and industry, and is expected to boost Greek research productivity and innovation in biomedicine.